Objective: To analyse the characteristics of opportunistic infections
in patients receiving highly active antiretroviral treatment (HAART).
Design and methods: A retrospective study performed in seven hospitals
, included all patients starting treatment by ritonavir or indinavir b
etween 26 March and 31 December 1996. Patients were evaluated for the
development of AIDS-defining events. Clinical evaluation, plasma HIV-1
RNA quantification, CD4 cell count were recorded at baseline and at t
he onset of the event. Results: Four hundred and eighty-six patients w
ere included: 44.2% had a CD4 cell count below 50 x 10(6) cells/l. Fif
ty clinical events were recorded in 46 patients with a mean follow-up
of 6.1 months, of which 34 events (68%) were observed during the first
2 months of HAART. Eighteen of these occurred despite a reduction of
vital load by at least 1.5 log(10) and a 100% increase of the CD4 cell
count compared with that at the onset of the event, corresponding to
11 cytomegalovirus us infections, five mycobacterial infections, one c
ase of cryptococcosis, and one case of Varicella-Zoster virus-related
acute retinal necrosis. Among the 16 events observed after the second
month, six occurred despite a marked biological improvement, correspon
ding to a recurrence in five of six patients who had stopped their mai
ntenance therapy. Events were one cytomegalovirus infection, two mycob
acterial infections, one episode of oesophageal candidiasis and one cr
yptococcal meningitis. Conclusion: In patients at high risk of develop
ing an opportunistic infection prior to the institution of a HAART reg
imen, prophylaxis should not be discontinued during the first 2 months
of treatment, and maintenance therapy should be carried on despite a
significant increase in the CD4 cell count. (C) 1998 Lippincott Willia
ms & Wilkins.